283O_PRPhase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer. (23rd October 2018) - Jiang, Z; Li, W; Hu, X; Zhang, Q; Sun, T; Cui, S; Wang, S; Ouyang, Q; Yin, Y; Geng, C; Tong, Z; Cheng, Y; et al.